<DOC>
	<DOCNO>NCT02266433</DOCNO>
	<brief_summary>The primary objective study compare local corticosteroid hand elbow injection placebo ketorolac determine equal good reduction symptom common orthopaedic upper extremity disorder include : De Quervain 's tenosynovitis , trigger finger , tennis elbow ( lateral epicondylitis ) . The investigator enroll 780 subject , divide equally three arm disease process , compare efficacy Ketorolac injection Dexamethasone injection measure patient 's functional status score pain score 0 week , 4 week , 8 week , 12 week , 6 month followup period , prospectively time .</brief_summary>
	<brief_title>Dexamethasone Versus Ketorolac Injection Treatment Local Inflammatory Hand Upper Extremity Disorders</brief_title>
	<detailed_description>Objectives : The primary objective study compare local corticosteroid hand elbow injection placebo ketorolac determine equal good reduction symptom common orthopaedic upper extremity disorder include : De Quervain 's tenosynovitis , trigger finger , tennis elbow ( lateral epicondylitis ) . Number Subjects : 780 total subject : • 260 subject 3 treatment group ( De Quervain 's tenosynovitis , trigger finger lateral epicondylitis ) Diagnosis Main Inclusion Criteria Subjects 18 year old , follow diagnosis : De Quervain 's tenosynovitis , trigger finger , lateral epicondylitis Study Product , Dose , Route , Regimen : Peritendinous soft tissue injection De Quervain 's tenosynovitis , trigger finger lateral epicondylitis : • 1 mL ketorolac ( 30mg/mL ) 0.5 mL ( 5mg ) 1 % lidocaine Duration administration Single administration , second injection permit subject desire due major clinical response 4 8-week follow-up . Reference therapy : Standard care peritendinous soft tissue injection De Quervain 's tenosynovitis , trigger finger , lateral epicondylitis : • 1 mL dexamethasone sodium phosphate ( 4mg/mL ) 0.5 mL ( 5mg ) 1 % lidocaine Statistical Methodology : The sample size state derived power analysis . A power analysis indicate total sample size 200 patient randomize equally ( 1:1 randomization ) treatment arm ( i.e trigger finger , De Quervain 's disease , tennis elbow ) without block stratification would provide 80 % statistical power ( alpha=.05 , beta=0.20 ) detect 10 % difference mean Quick Disabilities Arm , Shoulder Hand ( quickDASH ) score cohort assume common standard deviation 25 % ( effect size = 10/25 = 0.4 ) . To account estimated 30 % loss follow-up , investigator plan enroll total 260 patient per treatment arm ( i.e . trigger finger , De Quervain 's disease , tennis elbow ) . In total , approximately 780 patient enrol among treatment arm . 1.1 Background Many orthopaedic hand disorder comprise different form tendonitis , tenosynovitis , arthritis . The inflammatory process disorder cause discomfort functional impairment patient . Decreasing inflammatory response use splinting , physiotherapy , systemic anti-inflammatory agent , local anti-inflammatory injection help alleviate discomfort ( 2-4 ) . Steroid injection entirely benign , complication include tendon rupture , subcutaneous fat atrophy , skin pigmentation change , cartilage damage , hyperglycemic response diabetic ( 9-11 , 22-23 ) . Studies show ketorolac , non-steroidal anti-inflammatory agent potent anti-inflammatory effect comparable corticosteroid strong analgesic effect allow reduce opioid consumption postoperatively ( 7 , 8 ) . One could argue potent anti-inflammatory property ketorolac could use substitute local corticosteroid injection treat certain hand disorder . Given side-effect profile corticosteroid may beneficial treat inflammatory disorder local ketorolac injection . Nonsteroidal anti-inflammatory agent also know systemic adverse effect include gastric ulceration intestinal bleeding well impairment renal function . Most side effect theoretically avoid local tissue injection . 1.2 Study Drugs Ketorolac : The propose use ketorolac study outside FDA-approved indication investigational agent study Ketorolac non-steroidal anti-inflammatory drug ( NSAID ) . The approved indication Ketorolac short-term ( ≤5 day ) management moderately severe , acute pain require analgesia opioid level , usually postoperative setting . It highly protein bound ( 99 % ) largely metabolize liver . In 's approved indication contraindicate renal impairment , active peptic ulcer disease , pregnant nursing female , individual NSAID hypersensitivity , individual high risk bleeding/clotting disorder . Dexamethasone : Dexamethasone synthetic corticosteroid posse glucocorticoid activity , use within label indication study : intra-articular soft tissue injection : synovitis osteoarthritis , epicondylitis , acute nonspecific tenosynovitis . It active comparator study . In approved indication use limitation immunocompromised individual , pregnant female , person allergy steroid , individual systemic fungal infection , individual cerebral malaria . It contra-indicated systemic fungal infection , hypersensitivity component product , include sulfites . Lidocaine : Lidocaine local anesthetic amide type , use within label indication study : production local regional anesthesia infiltration technique percutaneous injection . It give concomitant therapy investigational agent , ketorolac injection , standard care therapy , dexamethasone injection .</detailed_description>
	<mesh_term>Tennis Elbow</mesh_term>
	<mesh_term>Trigger Finger Disorder</mesh_term>
	<mesh_term>Tenosynovitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must diagnose least one following : trigger finger , de quervain 's tenosynovitis , tennis elbow ( lateral epicondylitis ) Patients age 18 year age old racial/ethnic type Patient male female Study participant include New York University employee student individual also get hand upper extremity pathology . It specifically reiterate academic status grade , employment affect decision participate study . Record participation link academic record . Patients previous steroid injection site question within 90 day enrollment Patients history gastric ulcer , renal impairment , allergy/hypersensitivity nonsteroidal antiinflammatory ( NSAID ) lidocaine derivative medication , immunocompromised patient ( HIV/AIDs ) pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DeQuervains Tenosynovitis</keyword>
	<keyword>Lateral Epicondylitis</keyword>
	<keyword>Tennis Elbow</keyword>
	<keyword>Trigger Finger</keyword>
	<keyword>Tenosynovitis</keyword>
	<keyword>Inflammatory Disease</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Ketorolac</keyword>
	<keyword>Toradol</keyword>
</DOC>